Manchester University NHS Foundation Trust

Running trials

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  PS-002 for the Treatment of IgA Nephropathy in Adults

  NCT07182227· Phase 1/2· Purespring Therapeutics Limited· Source

• Recruiting

  Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

  NCT07120776· University of Manchester· Source

• Enrolling by invitation

  DENTOFACIAL-PBT Stage 2 - Feasibility Study

  NCT07057284· Manchester University NHS Foundation Trust· Source

• Recruiting

  A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

  NCT06904261· Phase 3· Amicus Therapeutics· Source

• Recruiting

  Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk

  NCT07067658· Heartfelt Technologies· Source

• Not yet recruiting

  The AcCREDiT 2 Study

  NCT07029672· Manchester University NHS Foundation Trust· Source

• Recruiting

  Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

  NCT06464926· Enterra Medical, Inc.· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Active, not recruiting

  Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention

  NCT07891988· University of Leicester· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· University College, London· Source

• Active, not recruiting

  Methylated Biomarkers Predictive of Endometrial Cancer Risk

  NCT06800677· University of Manchester· Source

• Active, not recruiting

  Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

  NCT06149650· Cardiovascular and Interventional Radiological Society of Europe· Source

• Recruiting

  Study of WAL0921 in Patients With Glomerular Kidney Diseases

  NCT06466135· Phase 2· Walden Biosciences· Source

• Recruiting

  HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)

  NCT06100211· University of Manchester· Source

• Recruiting

  Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

  NCT06355583· Phase 2· Imperial College London· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  NCT06308978· Phase 1· Fate Therapeutics· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

  NCT06049654· Fundación EPIC· Source

• Recruiting

  Detecting EARLY Heart Failure in Greater Manchester

  NCT05955456· Manchester University NHS Foundation Trust· Source

• Active, not recruiting

  Avacostar - (PASS)

  NCT05897684· Vifor Fresenius Medical Care Renal Pharma· Source

• Recruiting

  Rescue of Nephrons With ALE.F02 (RENAL-F02)

  NCT06047171· Phase 2· Alentis Therapeutics AG· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Recruiting

  Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

  NCT05234723· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  UK Heart Failure With Preserved Ejection Fraction

  NCT05441839· Manchester University NHS Foundation Trust· Source

• Recruiting

  Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)

  NCT05383287· Manchester University NHS Foundation Trust· Source

• Active, not recruiting

  A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

  NCT05181618· Phase 4· Hoffmann-La Roche· Source

• Active, not recruiting

  Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  NCT05407636· Phase 3· AbbVie· Source

• Recruiting

  Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

  NCT05003986· Phase 2· Travere Therapeutics, Inc.· Source

• Recruiting

  Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

  NCT04965298· Phase 3· Norfolk and Norwich University Hospitals NHS Foundation Trust· Source

• Recruiting

  A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

  NCT04319367· Phase 2· Imperial College London· Source

• Active, not recruiting

  The SELUTION DeNovo Study

  NCT04859985· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Recruiting

  Integrated Diagnostics for Early Diagnosis of Liver Disease

  NCT04666402· Manchester University NHS Foundation Trust· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Recruiting

  ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

  NCT04132895· University College, London· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

  NCT03671148· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· Phase 3· AbbVie· Source

• Active, not recruiting

  A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

  NCT02130362· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure4 recruiting
• IgA nephropathy3 recruiting
• ANCA-associated vasculitis2 recruiting
• Childhood cancers2 recruiting
• HIV2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Fabry disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Myelodysplastic syndromes1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  OASIS: RetrOspective Analysis on EEGs for Identifying Seizure Susceptibility in paediatrIcs Using biomarkerS

  NCT06546410· Neuronostics Ltd· Source

• Completed

  Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC

  NCT05971108· Phase 4· Manchester University NHS Foundation Trust· Source

• Completed

  A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

  NCT06166056· Phase 1/2· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

  NCT05923827· Insulet Corporation· Source

• Withdrawn

  Oxygen-enhanced Magnetic Resonance Imaging (OE-MRI) of the Heart: A Feasibility Study

  NCT05163327· Manchester University NHS Foundation Trust· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

  NCT04987489· Phase 2· Forma Therapeutics, Inc.· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

  NCT04706429· Phase 2· Manchester University NHS Foundation Trust· Source

• Completed

  A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

  NCT04451772· Phase 2· AbbVie· Source

• Completed

  Left Atrial Arrhythmia Substrate Identification After Confirmed durABLE Pulmonary Vein Isolation

  NCT04111731· Liverpool Heart and Chest Hospital NHS Foundation Trust· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· University of Bristol· Source

• Completed

  Percutaneous Deep Vein Arterialization Post-Market Study

  NCT03807661· LimFlow SA· Source

• Completed

  Trans People Living With HIV Throughout Europe

  NCT03922269· Chelsea and Westminster NHS Foundation Trust· Source

• Completed

  WORKWELL: Testing Work Advice for People With Arthritis

  NCT03942783· University of Salford· Source

• Completed

  Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  NCT03339128· Phase 2· AbbVie· Source

• Completed

  Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

  NCT02730299· Phase 3· Gamida Cell ltd· Source

• Completed

  A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

  NCT02782663· Phase 2· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma66 works · 0 trials
• COPD38 works · 1 trial
• Systemic sclerosis (scleroderma)33 works · 3 trials
• Cystic fibrosis32 works · 0 trials
• Rheumatoid arthritis28 works · 3 trials
• Endometrial cancer21 works · 1 trial
• Lupus (SLE)18 works · 3 trials
• Bronchiectasis15 works · 1 trial
• Psoriatic arthritis13 works · 3 trials
• Irritable bowel syndrome10 works · 1 trial
• Sarcoidosis8 works · 0 trials
• Retinitis pigmentosa7 works · 0 trials
• Mesothelioma6 works · 0 trials